# UniQure grants CSL Behring global rights to hemophilia B gene therapy

UniQure granted CSL Behring exclusive global rights to commercialize its AAV gene therapy program AMT-061 for hemophilia B, in a licensing deal potentially worth up to $2 billion.

- Type: Contract
- Announced: 2020-06-25
- Value: $2.00B
- Status: announced
- Products: gene therapy for hemophilia B

## Companies

- [UniQure](https://endata.com/companies/48119.md)
- [CSL Behring](https://endata.com/companies/28726.md) (customer)

## Sources

- [globalgenes.org](https://globalgenes.org/raredaily/uniqure-grants-csl-behring-global-rights-to-hemophilia-b-gene-therapy/), 2020-06-25: "In a licensing agreement potentially worth up to more than $2 billion, Uniqure has granted CSL Behring exclusive global rights to commercialize its adeno-associated virus (AAV) gene therapy program for the treatment of hemophilia B."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.